Clinical trials: sponsored by Boryung Pharmaceutical Co., Ltd
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
- Trial name
- NCT06314919
- Where
- South Korea
- Volunteers
- 8,606 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension,Essential
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or…
- Trial name
- NCT05413057
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Cancer
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery
- Trial name
- NCT06537752
- Where
- 2 sites in South Korea
- Volunteers
- 1,052 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabete Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B,"…
- Trial name
- NCT07083401
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A"…
- Trial name
- NCT07083388
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hepatitis A Vaccine
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)
The objective of this study is to evaluate the safety and immunogenicity after one primary dose and one additional dose (administered twice at an interval of 6 months) of inactivated hepatitis A vaccine are administered in…
- Trial name
- NCT03654677
- Testing
- inactivated hepatitis A vaccine, Havrix Inj
- Where
- 12 sites in South Korea
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Metastatic Adenocarcinoma of the Pancreas
A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1
The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas
- Trial name
- NCT06867497
- Testing
- BR2021, BR2021-1
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744127
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744426
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744062
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions
- Trial name
- NCT06890299
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting…
- Trial name
- NCT06890286
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetic, pharmacodynamic characteristics and the safety after administration by doses of "BR1400-1", "BR1400-2", "BR1400-3" in healthy volunteers
- Trial name
- NCT06889064
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fed Conditions
- Trial name
- NCT06879132
- Testing
- BR3409, BR3409-1, BR3409-2
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fasting Conditions
- Trial name
- NCT06879158
- Testing
- BR3409, BR3409-1, BR3409-2
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Erosive Esophagitis
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
- Trial name
- NCT01499368
- Testing
- Lafutidine, Famotidine, Omeprazole
- Volunteers
- 495 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd